Long acting GLP-1 receptor agonist (injectable)
Dulaglutide 1.0 mg injection once weekly
DULA_SC_1p0MG_QW
Related
- All doses pooled: Dulaglutide injection
- Dulaglutide 1.5 mg subcutaneous once weekly
- Dulaglutide 3.0 mg subcutaneous once weekly
- Dulaglutide 4.5 mg subcutaneous once weekly
- Dulaglutide 0.25 mg injection once weekly
- Dulaglutide 0.5 mg injection once weekly
- Dulaglutide 0.75 mg subcutaneous once weekly
- Dulaglutide flexible dose injection once weekly
- Dulaglutide 2.0 mg injection once weekly
- Dulaglutide 0.1 mg injection once weekly
- Dulaglutide 0.75 mg injection
Effects across outcomes
Bayesian random effects estimate against the comparator of each analysis (usually placebo), posterior median and 95% credible interval. Green: clearly better; red: clearly worse.
| Condition | Outcome | Window | Versus | Effect (95% CrI) | SUCRA |
|---|---|---|---|---|---|
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 0.39 (0.01 to 19.14) | 0.50 |
| Type 2 diabetes (adults) | Serious adverse events | longest follow-up | Placebo | HR 1.57 (0.41 to 6.52) | 0.32 |
| Type 2 diabetes (adults) | Nausea | longest follow-up | Placebo | HR 2.81 (1.17 to 6.87) | 0.47 |
| Type 2 diabetes (adults) | Vomiting | longest follow-up | Placebo | HR 0.64 (0.15 to 2.51) | 0.81 |
| Type 2 diabetes (adults) | Diarrhea | longest follow-up | Placebo | HR 0.81 (0.31 to 2.08) | 0.76 |
| Type 2 diabetes (adults) | Constipation | longest follow-up | Placebo | HR 2.08 (0.65 to 6.62) | 0.41 |